Financial comparisons Perspective Therapeutics, Inc.
Stocks
CATX
US46489V3024
Biotechnology & Medical Research
|
Market Closed -
NYSE
16:00:00 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 3.130 USD | +0.32% |
|
+0.64% | +13.82% |
| 08-19 | BMO Capital Initiates Perspective Therapeutics at Outperform | MT |
| 08-14 | BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6 | MT |
Main competitors
| Revenues (N-1) | Net Margin (N-1) | EBIT Margin (N-1) | ROE (N-1) | ROA (N-1) | Leverage (N-1) | ||
|---|---|---|---|---|---|---|---|
 | 884K | -11,665.27% | -12,846.61% | -41.44% | - | 1.3x | |
| 8.24B | 14.53% | 21.7% | 10.28% | 4.9% | 1.58x | |
| 16.31B | 8.34% | 13.38% | 32.9% | 4.79% | 3.63x | |
| 5.34B | 5.37% | 8.37% | 29.84% | 16.27% | -5.99x | |
| 2.88B | 24.74% | 28.07% | 5.94% | 4.75% | 1.77x | |
| 846M | -31.67% | -18.92% | - | - | 1.57x | |
| 2.53B | 17.83% | 20.93% | 70.23% | 22.13% | -0.89x | |
| 8.57B | 6.51% | 14.79% | 9.61% | 4.34% | 2.22x | |
| 4.02B | -3.59% | 19.77% | 15.46% | 6.99% | 1.98x | |
| 8.25B | 2.78% | 16.66% | 10.62% | 6.02% | 1.8x | |
| 1.27B | -19.27% | -3.71% | -38.64% | -6.61% | -65.61x | |
| 1.22B | 14.97% | 31.77% | 15.06% | 11.79% | -0.15x | |
| 5.4M | -7,306.52% | -5,350% | -135.58% | - | 2.1x | |
| 2.02B | 11.8% | 13.68% | 11.6% | 6.52% | 1.83x | |
| 39.21M | -794.04% | -891.07% | -25.78% | -22.89% | 4.75x | |
| 944M | -40.36% | -40.47% | -70.72% | -11.67% | 4.51x | |
| 46.02M | -282.83% | -343.63% | -20.18% | -18.42% | 0.82x | |
| 2.09B | 20.33% | 29.46% | 17.5% | 10.73% | 0.74x | |
| Average | 3.59B | -1,112.02% | -1,070.88% | -6.08% | 2.64% | -2.34x | |
| Weighted average by Cap. | 5.73B | -259.89% | -200.13% | 8.32% | 5.35% | -1.46x |
- Stock Market
- Stocks
- CATX Stock
- Sector Perspective Therapeutics, Inc.
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
